Peptides & Longevity
GLP-1s were the entry point. The wider peptide category — recovery, body composition, and longevity compounds — is where the field is heading. What to stack, what the evidence actually shows, and how to access it through legitimate channels.
Peptide Stacks
What to stack with a GLP-1 for body recomposition.
BPC-157 With a GLP-1
Whether BPC-157 pairs with semaglutide or tirzepatide, and what the evidence shows.
Peptides to Take With a GLP-1
Ipamorelin, BPC-157, TB-500, and MOTS-c ranked by how much evidence actually backs pairing each with a GLP-1.
Retatrutide and BPC-157
Why retatrutide is a different situation than semaglutide or tirzepatide, and the legal access gap that matters more than the pharmacology.
The Peptide Thesis
Why GLP-1s were just the start of the peptide era.
What Is Epitalon?
A telomere and melatonin peptide FDA staff actually reviewed for insomnia, not anti-aging, ahead of the July 23-24, 2026 hearing.
What Is KPV?
A three-amino-acid alpha-MSH fragment studied for gut and skin inflammation. FDA staff found zero human safety data ahead of the July 23-24, 2026 hearing.
What Is Tesamorelin?
The FDA-approved growth hormone peptide behind an 18% visceral fat drop in a 2007 NEJM trial, and why the off-label market has outrun the evidence.
What Is GHK-Cu?
A copper-binding peptide with real topical skin trial data. The injectable form, reclassified by the FDA in April 2026, has none, and a separate FDA review is not due until February 2027.
What Is Semax?
A Russian stroke drug sold in the US as a nootropic. FDA staff could not find one human pharmacokinetic study for it, by any route, ahead of the July 2026 PCAC vote.
What Is DSIP?
A 1977 rabbit-blood sleep peptide with no known receptor. The only one of seven peptides an FDA panel rejected for compounding, 6-7, on July 24, 2026.
What Is Ipamorelin?
A selective growth hormone peptide with real human trial history. Its one efficacy trial failed, and an FDA panel already voted against compounding it in October 2024.
What Is MOTS-c?
A mitochondrial-derived peptide studied as an exercise mimetic. FDA staff recommended against adding it to the 503A compounding list ahead of the July 23-24, 2026 hearing.
